Search results for "Talipexole"

showing 3 items of 3 documents

Dopamine Autoreceptor Agonists in the Treatment of Schizophrenia and Major Depression*

1992

Dopamine autoreceptor agonists reduce the firing rate, synthesis, and release of dopamine in dopaminergic neurons by means of a negative feedback mechanism via stimulation of autoreceptors. Moreover, dopamine autoreceptor agonists are able to stimulate supersensitive but not normosensitive postsynaptic receptors. For dopamine autoreceptor agonists, therapeutic effects by readjustment of excessive or deficient dopaminergic function have been postulated for positive and negative schizophrenic symptomatology as well as for subtypes of depressive disorders. Investigations on the therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia or depression have yielded incons…

Depressive Disordermedicine.medical_specialtyDopamine AgentsDopaminergicGeneral MedicineDopamine agonistTalipexolePsychiatry and Mental healthchemistry.chemical_compoundEndocrinologyRoxindolechemistryDopamine receptorDopamine receptor D3DopamineInternal medicineSchizophreniamedicineAutoreceptorAnimalsHumansPharmacology (medical)PsychiatryPsychologymedicine.drugPharmacopsychiatry
researchProduct

Dopamine autoreceptor agonists in the treatment of schizophrenic disorders

1993

Abstract 1. Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a negative feedback regulation, investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results. 2. With respect to the dopamine hypothesis of schizophrenia, dopamine autoreceptor agonists have been tested in positive schizophrenic symptomatology in order to reduce the postulated excess of central dopaminergic activity. However, administration of selective dopamine autoreceptor agonists like talipexole or roxindole did not result in a significant improvement of psychopathologic…

Pharmacologymedicine.medical_specialtyPramipexoleDopamine AgentsDopaminergicTalipexoleEndocrinologyDopamine receptorDopamine receptor D3DopamineInternal medicineDopamine receptor D2SchizophreniamedicineAutoreceptorHumansSchizophrenic PsychologyPsychologyBiological Psychiatrymedicine.drugClinical psychologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Dopamine agonists in schizophrenia: a review.

1995

Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology. Synthesis and release of dopamine as well as firing rates of dopaminergic neurons are controlled by stimulation of autoreceptors via a negative feedback regulation. Investigations on therapeutic effects of autoreceptor-nonselective dopamine agonists in schizophrenia have yielded inconsistent results. Dopamine autoreceptor agonists like pramipexole, roxindole,…

medicine.medical_specialtychemistry.chemical_compoundNeurochemicalPramipexoleRoxindoleDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineHumansPharmacology (medical)BenzothiazolesBiological PsychiatryAutoreceptorsPharmacologyPramipexoleDopaminergicAzepinesTalipexolePsychiatry and Mental healthThiazolesEndocrinologyNeurologychemistryDopamine AgonistsSchizophreniaNeurology (clinical)Psychologymedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct